Shares of Cencora Inc. COR slid 2.56% to $254.00 Wednesday, on what proved to be an all-around mixed trading session for the ...

Cencora (NYSE:COR) has made headlines with its announcement on March 10, 2025, detailing plans for strategic acquisitions and investments in technology infrastructure, aiming to drive future growth.

Proficio Capital Partners LLC bought a new position in Cencora, Inc. (NYSE:COR – Free Report) in the 4th quarter, according ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Wells Fargo raised the firm’s price target on Cencora (COR) to $274 from $251 and keeps an Equal Weight rating on the shares. The firm is ...

Cencora (NYSE:COR) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...

Have you been paying attention to shares of Cencora (COR)? Shares have been on the move with the stock up 6.2% over the past month. The stock hit a new 52-week high of $262.56 in the previous session.

Cencora offers steady revenue growth from pharmaceutical distribution, benefiting from rising healthcare demand and an aging population. Learn more on COR stock here.

With a market cap of $50.5 billion, Conshohocken, Pennsylvania-based Cencora, Inc. (COR) is a global healthcare solutions provider specializing in pharmaceutical distribution and related services.

Equities research analysts at Zacks Research decreased their Q2 2025 earnings per share (EPS) estimates for Cencora in a note ...

With a market cap of $50.5 billion, Conshohocken, Pennsylvania-based Cencora, Inc. (COR) is a global healthcare solutions ...